A double blind placebo controlled trial investigating the efficacy of Clopidogrel as prophylactic treatment for migrane. - Clopidogrel as prophylactic treatment for migrane

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2008-001604-23-GB

Enrollment

286

Registered

2008-10-29

Start date

2008-12-03

Completion date

Unknown

Last updated

2018-11-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine MedDRA version: 9.1 Level: LLT Classification code 10027599 Term: Migraine

Interventions

Trade Name: PLAVIX Pharmaceutical Form: Film-coated tablet CAS Number: 135046489 Other descriptive name: CLOPIDOGREL HYDROGEN SULFATE Concentration unit: mg milligram(s) Concentration type: equal Conc

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Participants aged > 18 Definite migraine with or without aura as defined by International Headache criteria Headache or aura occurring on 4 or more days and less than 15 days in a 28 day month Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: High risk features suggesting cerebral malignancy, More than 15 headache days each month Contraindications to clopidogrel therapy (hypersensitivity, active bleeding, warfarin therapy, hepatic dysfunction) Already prescribed clopidogrel (recent acute coronary syndrome, TIA with aspirin hypersensitivity) Requirement for routine nonsteroidal anti-inflammatory agents (occaisional use is allowed) Use of an investigational product within the previous 3 months Clinically significant abnormal platelet or liver function at visit 1

Design outcomes

Primary

Measure	Time frame
Main Objective: 1. To determine the incidence of 'patent ovale and atrial septal aneurysm in consecutive migraineurs. 2. To test whether Clopidogrel is effective prophylaxisi in consecutive migraineurs 3. To determine the effect of a patent foramen ovale or atrial septal aneurysm on the efficacy of clopidogrel. 4. To compare efficacy of Clopidogrel in migraine with and without aura.;Secondary Objective: ;Primary end point(s): The number of headache days in 28 days Secondary: (1) The severity and (2) duration of migraine attacks in 28 days and the number of responders.	—

Measure

Time frame

Main Objective: 1. To determine the incidence of 'patent ovale and atrial septal aneurysm in consecutive migraineurs. 2. To test whether Clopidogrel is effective prophylaxisi in consecutive migraineurs 3. To determine the effect of a patent foramen ovale or atrial septal aneurysm on the efficacy of clopidogrel. 4. To compare efficacy of Clopidogrel in migraine with and without aura.;Secondary Objective: ;Primary end point(s): The number of headache days in 28 days Secondary: (1) The severity and (2) duration of migraine attacks in 28 days and the number of responders.

—

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026